WHO WE ARE
Located in Laguna Hills, California, USA, and Mont St-Guibert, Belgium, Metronom Health—which is a portfolio company of Fjord Ventures LLC, a life science technology accelerator—is a thriving, fast-paced development company with an entrepreneurial environment.
Leveraging its accelerator operating model, Fjord Ventures creates capital-efficient companies. These efficiencies are achieved through the broad experience of management, shared infrastructure and a dedicated source of funding that allows Fjord’s portfolio companies to focus on product innovation and disruptive technologies. This culture incentivizes progress and nurtures highly motivated, idea-driven spaces, where groundbreaking technology like Metronom Health Continuous Glucose Monitoring can take hold.
Metronom Health is prepared to revolutionize the management of diabetes.
We envision a world where the effort of diabetes management does not consume the lives of people living with diabetes, as well as those who care for them: Less thinking. Less worrying. More doing. This principle is at the core of the development of our solution. That is our daily, unwavering focus at Metronom Health.
Leveraging its innovative and unique technology, Metronom is committed to developing and commercializing a revolutionary Continuous Glucose Monitoring solution, which will be deeply rooted in users’ individual needs, and shaped by the overall healthcare system, aiming to define a new standard of care in the management of diabetes.
OUR LEADERSHIP TEAM: COMMITTED TO MAKING IT HAPPEN
Michel Lussier, CEO
Michel Lussier serves as Chief Executive Officer of Metronom Health, Inc. and is an advisor to other Fjord Ventures portfolio companies. Michel is also the co-founder of Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, as well as the co-founder of Cardio3 BioSciences and has served as Chairman of the Board of Directors since Cardio3 BioSciences’ inception in July 2007. He has been the Managing Director of Volcano Europe since March 2006. From July 2002, Michel has also served as Volcano President, General Manager of Europe, Africa and Middle East and Global Clinical and Scientific Affairs. In February 2002, he founded Medpole S.A./N.V., a European distribution incubator for medical device start-up companies located in Belgium. From October 1998 to January 2002, he served as the Vice President and General Manager, Europe, of Novoste Corp., a medical technology company.
Prior to Novoste, Michel founded and led the European subsidiary of InControl Corp., until its acquisition by Guidant Corporation. He brings 15 years of operational experience with Medtronic, Inc., where he drove the company's core business in Europe as Business Director, Cardiac Pacing. Additionally, Michel holds a director mandate in Medpole S.A. and has chaired a number of committees within Eucomed, as well as serving on several start-up boards for medical devices. Michel received a B.S. in Electrical Engineering and an M.S. in Biomedical Engineering from the University of Montreal, Canada, and an M.B.A. from INSEAD, France.
Troy Bremer, Co-Founder, Chief Scientific Officer
Troy Bremer is co-founder and Chief Scientific Officer at Metronom Health, and has been an integral part of the company since its inception.
Troy is passionate about improving healthcare through innovation. His research background has involved the application of machine learning, statistical pattern recognition, modeling and biostatistics to molecular biology. He has expertise in the planning, management, analysis and execution of complex research and development programs.
Troy has extensive experience in diagnostic development and previously identified and validated several biomarker panels for disease prognosis and treatment response in oncology, leading to a number of publications and various patents. He is also co-founder and Chief Scientific Officer for PreludeDx, a Fjord Ventures portfolio company, founded in 2009 whose mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system. Prior to PreludeDx and Metronom Health, Troy worked at Lion Biosciences and Prediction Sciences where he served as Director of Research and Development.
Troy received his Doctorate in Biomedical Engineering from the University of California, San Diego.
Mel Waite, VP Operations
Mel Waite brings more than 30 years of executive-level Operations Management and Manufacturing leadership experience in a variety of world-class, international and high-volume production environments, which includes 12 years (1982 to 1995) with Apple Computer/Alps Electric in high-volume Personal Computer and Computer Peripheral Manufacturing. From 1995 through 1998, Mel served as VP Operations for VitalCom, Inc., a public medical device company that manufactured and marketed an RF-based cardiac monitoring system. Mel was part of the executive team that took the company through the IPO process in 1996, and was also responsible for building and refining the manufacturing systems. From 1998 to 2005, he was the Vice President of Operations for Robert Shaw Controls (a Division of Invensys Ltd). In this position, he was responsible for global manufacturing operations and had more than 2,500 employees within his manufacturing organization. From 2005 through 2013, he held a series of Manufacturing Consulting roles in both commercial and medical device organizations.
Mel's experience in building and refining truly world-class manufacturing operations in a wide cross section of products and markets has been a key factor in Metronom’s evolution from purely an R&D company to a commercial manufacturing company.
Martin Lafontaine, VP Marketing
Martin Lafontaine joined Metronom Health in January 2017, as Head of Marketing and Business Development. Martin has 18 years of experience within the pharmaceutical, medical device and digital health industry. Martin has held various leadership positions in the commercial organization in both multinational (GlaxoSmithKline) and start-up organizations, in North America and Internationally. Most recently, Martin occupied the role of Chief Commercial Officer at Locemia Solutions Inc., a small Canadian-based diabetes pharma company, where he played an instrumental role in the development and sale of the Nasal Glucagon asset to Eli Lilly and Company, in October 2015.
Martin possesses strong expertise in commercial go-to-market product launch excellence, marketing, corporate development and business development, solidly anchored in the field of diabetes. Martin is active on the board or serves as an advisor to several diabetes-related organizations in both the for- and not-for-profit sectors. His passion for diabetes has solid roots, beginning at age 13 when he was diagnosed with type 1 diabetes. Martin graduated in 1998 with a Bachelor in Sciences, from l’Université du Québec à Trois-Rivières.
Hervé Mével, VP Development & Manufacturing
Hervé Mével joined Metronom Health in July 2017, as vice president development and manufacturing. Hervé brings along more than 15 years in product development of medical devices with CE mark certifications. Prior to joining Metronom, Hervé held the position of Research and Development Director for CAIRDAC, a company focusing on the development of a new leadless pacemaker with energy harvester.
In his previous professional experiences, Hervé has been part of the Sorin Group, where he was Product Development Program Director, for the design and the development of an Active Implantable Medical Device combining pacing and defibrillation features to treat heart failure. He also worked for the University of Louvain (UCL), as well as for Neurotech SA, a spin-off of the UCL, in the area of AIMD neuromodulation. Hervé received his Master of Science in Industrial Engineering at the HEI of the Province de Liège.
Ursula Morjaria, VP Clinical & Regulatory Affairs
Ursula Morjaria joined Metronom Health in July 2017, and is leading the Regulatory Affairs and the Clinical development. She is a seasoned clinical research professional who held leadership positions in corporate organizations such as Medtronic, GE Healthcare, Abbott Vascular (previously Guidant) and the EORTC, as well as startups such as Celyad (previously Cardio3 Biosciences) and OrbusNeich Medical. Recently, she has been leading the development of the Clinical Trial Unit of the Clinique Universitaire Saint-Luc, Belgium, in order to strengthen and professionalize clinical operations across the institution. Her experience covers Pharma as well as Medical Devices.
Ursula holds a B.Sc. in Medical Biology from the University of Louvain, UCL, Brussels, a post-university degree in Marketing Management from ICHEC as well as an MBA from the Solvay Brussels School of Economics and Management.
Dimitri Crelot, Director Finance
Dimitri Crelot joined Metronom Health full time in May 2017 as Director Finance, having previously help to set up the company subsidiary in Europe at the end of 2016. Prior to joining Metronom Health, Dimitri held a similar position for Keemotion, an early stage company active in the automatic production of sport content.
Dimitri is founder and co-founder of two companies, one active in the Wine and Spirits market, and the other one specialized in Marketing for SMEs.
In his previous professional experiences, Dimitri spent 6 years as Trader in the Financial Markets at BNP Paribas Fortis, and 6 years as Senior Risk Manager at Belfius Bank.
Dimitri graduated from Solvay Business School (Brussels) in 2000.